Synthesis, Anticancer Assessment, and Molecular Docking of Novel Chalcone-Thienopyrimidine Derivatives in HepG2 and MCF-7 Cell Lines

Table 2

Preliminary screening of the cytotoxic efficacy of the synthesized chalcone-thienopyrimidine derivatives 3a-g against human breast cancer cell line (MCF-7) compared to DMSO. The cytotoxic efficacy of the compounds is expressed as the mean of survival percentage ± SEM.

Compound concentration (μg/ml)	3a	3b	3c	3d	3e	3f	3g	DMSO
10000	6.0 ± 0.063	17.3 ± 0.001	5.9 ± 0.002	5.8 ± 0.001	15.9 ± 0.002	4.6 ± 0.002	15.3 ± 0.000	4.2 ± 0.071
5000	6.0 ± 0.001	19.7 ± 0.002	6.4 ± 0.007	6.12 ± 0.003	16.0 ± 0.000	5.1 ± 0.003	18.9 ± 0.001	4.2 ± 0.121
2500	6.28 ± 0.003	20.1 ± 0.001	6.4 ± 0.003	6.2 ± 0.005	17.9 ± 0.002	6.2 ± 0.004	19.0 ± 0.001	6.8 ± 0.257
1250	9.8 ± 0.003	20.3 ± 0.001	7.4 ± 0.003	8.5 ± 0.006	27.8 ± 0.021	47.5 ± 0.181	19.9 ± 0.002	11.5 ± 0.112
625	64.9 ± 0.008	20.3 ± 0.002	11.3 ± 0.026	26.5 ± 0.120	38.0 ± 0.030	67.1 ± 0.086	19.9 ± 0.001	15.1 ± 0.313
312.5	101.6 ± 0.022	21.0 ± 0.001	71.1 ± 0.156	35.3 ± 0.044	61.5 ± 0.112	92.0 ± 0.141	19.4 ± 0.004	26.8 ± 0.245
156.25	101.8 ± 0.284	21.3 ± 0.013	110.9 ± 0.063	103.1 ± 0.202	104.2 ± 0.026	119.7 ± 0.182	20.1 ± 0.003	102.6 ± 0.632
78.125	108.4 ± 0.084	27.7 ± 0.026	121.5 ± 0.183	113.1 ± 0.171	109.2 ± 0.084	120.2 ± 0.150	28.0 ± 0.015	113.0 ± 0.334
39.0625	129.1 ± 0.038	31.8 ± 0.009	132.0 ± 0.136	132.7 ± 0.231	129.1 ± 0.033	122.6 ± 0.121	81.0 ± 0.009	116.8 ± 0.277
19.53125	124.4 ± 0.079	83.2 ± 0.022	140.3 ± 0.197	133.2 ± 0.116	123.4 ± 0.070	127.7 ± 0.180	96.4 ± 0.003	129.7 ± 0.299
9.765625	132.9 ± 0.132	102.6 ± 0.015	135.4 ± 0.066	146.0 ± 0.065	131.6 ± 0.132	132.2 ± 0.214	98.2 ± 0.023	130.2 ± 0.226
4.8828125	150.0 ± 0.171	104.9 ± 0.016	149.3 ± 0.082	133.8 ± 0.227	147.1 ± 0.051	149.7 ± 0.082	105.3 ± 0.032	145.8 ± 0.072